To analyze the potential therapeutic relevance of Bcl-2-targeted therapy and mechanisms promoting cell death resistance in chemoresistant bladder cancer, we established cisplatin- and gemcitabine-resistant cell lines. Here, BCL2 is linked to urinary bladder carcinoma.